Brian Meehan

Brian Meehan

Auto-generated profile, based on publicly available information

Brian Meehan

Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2025 in Science Advances
Verified
Journal Article
Open access
LALata Adnani
Lata Adnani
BMBrian Meehan
Brian Meehan
MKMinjun Kim
Minjun Kim
DCDongsic Choi
Dongsic Choi
CRChristopher E. Rudd
Christopher E. Rudd
JRJanusz Rak
Janusz Rak
Aggressive brain tumors often exhibit immunologically ‘cold’ microenvironment, where the vascular barrier impedes effective immunotherapy in poorly understood ways. Tumor vasculature also plays a pivotal role in immunoregulation and antitumor immunity. Here, we show that small GTPase Rab27 controls the vascular morphogenesis and permeability for blood content and immune effectors. Thus, in Rab27a/b double knock out (Rab27-dKO) mice, the brain vasculature is abnormally scarce, while the blood vessels become dysmorphic and hyperpermeable in the context of brain tumors, including syngeneic glioblastoma. These defects are reflected in rearrangements of endothelial cell subpopulations with underlying diminution of venous endothelial subtype along with changes in gene and protein expression. Notably, Rab27-dKO brain endothelial cells exhibit deficient tight junctions, whereby they enable large-scale extravasation of cytotoxic T cells into the tumor mass. We show that Rab27-regulated vascular T cell infiltration can be exploited to enhance adoptive T cell therapy in syngeneic brain tumors.